Statements (22)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:public_company
|
gptkbp:CEO |
gptkb:Paul_J._Diaz
|
gptkbp:country |
gptkb:United_States
|
gptkbp:CUSIP |
62855J104
|
gptkbp:foundedYear |
1991
|
gptkbp:hasCompany |
gptkb:Myriad_Genetics,_Inc.
|
gptkbp:headquartersLocation |
gptkb:Salt_Lake_City,_Utah,_United_States
|
https://www.w3.org/2000/01/rdf-schema#label |
NASDAQ: MYGN
|
gptkbp:industry |
gptkb:biotechnology
|
gptkbp:ISIN |
US62855J1043
|
gptkbp:listedOn |
gptkb:NASDAQ
|
gptkbp:marketCap |
mid-cap
|
gptkbp:products |
molecular diagnostics
genetic testing hereditary cancer tests oncology tests |
gptkbp:stockSymbol |
gptkb:NASDAQ
gptkb:MYGN |
gptkbp:tradedOn |
gptkb:MYGN
|
gptkbp:website |
https://www.myriad.com/
|
gptkbp:bfsParent |
gptkb:Myriad_Genetics
|
gptkbp:bfsLayer |
7
|